All PolarisDMD sites are now launched!

We are thrilled to announce that all 40 sites, across 8 countries, are now fully launched for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy! What’s more, clinical trial sites are enrolling rapidly. There is limited space in the United States, Canada and Australia and sites in the UK, Germany, Ireland, Sweden, and Israel are at capacity. **We anticipate that the final patient screening visits will be completed in September, so please let us know if you have any questions about the trial at DMDtrials@catabasis.com**

PolarisDMD PATIENT EXPERIENCE

Have you ever wondered what the process is like to participate in a clinical trial from beginning to end? Here’s a snapshot!

**Within 28 days after passing SCREENING, you’ll attend the Baseline visit and be randomly assigned to take edasalonexent or a placebo. In PolarisDMD, 2 boys receive edasa for each boy that receives placebo.**

**Boys begin taking study drug at Baseline and continue for the next 52 weeks, with a total of 5 site visits over 12 months.**

**After 52 weeks, you can opt to transition to an open-label extension study, GalaxyDMD, where boys and their eligible siblings receive edasa.**
HERE ARE A COUPLE OF FREQUENTLY ASKED QUESTIONS

Q  When will we get results from the PolarisDMD trial?  
A  After the 1-year trial is complete, we will analyze the results. We expect to have the top-line results in the second half of 2020. We will share those results with you as soon as we are able to!

Q  Will I find out if my son received edasalonexent or placebo in the PolarisDMD trial?  
A  PolarisDMD will be complete after the last boy in the trial completes 1 year of treatment. The trial data will be analyzed and shared publicly. After the data has been unblinded, you will have the opportunity to learn from your physician if your son received placebo or edasalonexent.

ABOUT EDASALONEXENT

Edasalonexent inhibits NF-κB, a protein that plays a fundamental role in skeletal and cardiac muscle disease in Duchenne. By inhibiting NF-κB, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasa is being developed as a potential stand-alone therapy and may also have the potential to be combined with dystrophin-targeted therapies.

MAKING COMMUNITY CONNECTIONS

Jett Foundation Family Workshops—Catabasis will attend the workshop in Rochester, NY on September 14th. Learn all about Jett Foundation’s national education program at www.jettfoundation.org/familyworkshops

PPMD End Duchenne Tour—Catabasis will also be in Wilmington, DE on September 14th. To learn about PPMD’s efforts to reach every single family facing a Duchenne diagnosis in the US, visit www.parentprojectmd.org/get-involved/attend-events/end-duchenne-tour

CureDuchenne Cares—Catabasis will attend the CureDuchenne Cares workshop on September 28 in Richmond, VA. Learn all about these immersive, educational workshops at www.cureduchenne.org/workshops

Stay in touch!
Join our mailing list: http://www.catabasis.com/patients-families/for-further-information.php
Follow us on social media: @CatabasisPharma.
Ask a question about the trial: DMDtrials@catabasis.com

The information provided here is for parents and caregivers of boys with Duchenne muscular dystrophy. Edasalonexent is an investigational drug that is not yet approved in any territory.